Literature DB >> 23999214

Haematological cancer: Treatment of smoldering multiple myeloma.

S Vincent Rajkumar1, Robert A Kyle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23999214     DOI： 10.1038/nrclinonc.2013.160

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

2.  Diagnosis of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Dirk Larson; Robert A Kyle
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

3.  Haematological cancer: Redefining myeloma.

Authors:  S Vincent Rajkumar; Giampaolo Merlini; Jesus F San Miguel
Journal:  Nat Rev Clin Oncol       Date:  2012-07-31       Impact factor: 66.675

Review 4.  Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

Authors:  Joan Bladé; Meletios Dimopoulos; Laura Rosiñol; S Vincent Rajkumar; Robert A Kyle
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

5.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

Review 6.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

7.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

8.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

9.  Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.

Authors:  J T Larsen; S K Kumar; A Dispenzieri; R A Kyle; J A Katzmann; S V Rajkumar
Journal:  Leukemia       Date:  2012-10-16       Impact factor: 11.528

10.  Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.

Authors:  E Kastritis; E Terpos; L Moulopoulos; M Spyropoulou-Vlachou; N Kanellias; E Eleftherakis-Papaiakovou; M Gkotzamanidou; M Migkou; M Gavriatopoulou; M Roussou; A Tasidou; M A Dimopoulos
Journal:  Leukemia       Date:  2012-11-06       Impact factor: 11.528
  10 in total
  4 in total

1.  Treatment of smoldering multiple myeloma.

Authors:  Alessandro Gozzetti; Marzia Defina; Monica Bocchia
Journal:  Nat Rev Clin Oncol       Date:  2013-11-19       Impact factor: 66.675

Review 2.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Authors:  Vernon Wu; Erin Moshier; Siyang Leng; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Madhu Mazumdar; Samir Parekh; Ajai Chari
Journal:  Blood Adv       Date:  2018-06-26

Review 4.  Interpretation of cytogenetic results in multiple myeloma for clinical practice.

Authors:  A M Rajan; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-30       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.